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SummAry
A systematic review of the economic literature of cochlear implants (Ci) was conducted with the aim of summarizing the results of studies 
on the cost effectiveness of monolateral and bilateral (sequential/simultaneous) Ci in adult patients affected by severe to profound prelin-
gual and postlingual hearing impairment. The literature search was performed using “Pubmed mEDlinE” and the Centre for reviews and 
Dissemination search engines. inclusion criteria related to economic evaluation included primary studies published in English language 
from January 2000 to may 2010 and aimed to quantify costs of Ci and compare monolateral Ci vs. acoustic prosthesis and bilateral (se-
quential/simultaneous) Ci vs. monolateral Ci in terms of cost per unit of effectiveness. Four articles were identified. The mean direct medi-
cal cost of the monolateral Ci varied from € 30,026 to € 45,770 in postlingually deafened patients, and the cost of device represented the 
main cost component. Additional median costs of simultaneous and sequential bilateral Ci were, respectively, € 21,831 and € 25,459. The 
mean direct medical cost of monolateral Ci was € 31,942 in prelingually deafened patients. The monolateral Ci in postlingually deafened 
patients represented a cost effective intervention as compared with no implant (€ /QAly varied from € 7,930, € 24,983 to € 33,094). mon-
olateral Ci were not a cost effective intervention for traditional patients with more than 40 years of hearing impairment (€ 64,604/QAly) 
or for patients with marginal benefits from using acoustic prosthesis with more than 30 years of hearing impairment (€ 106,267/QAly). 
The cost effectiveness of monolateral Ci worsened with increasing age (€ /QAly from € 23,439 for patients < 30 years old to € 55,369 
for patients > 70 years). Bilateral Ci in postlingually deafened patients were less cost effective than monolateral Ci (from € 91,943/QAly 
to € 102,640/QAly). monolateral Ci were cost effective in prelingually deafened patients (€ /QAly: € 8,096). given the few economic 
evaluation studies in literature, future researches are needed to support the cost effectiveness results of Ci in adults and to evaluate the cost 
effectiveness of bilateral Ci, as well as to estimate the non-medical direct and indirect cost components.
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riASSunTo
La revisione sistematica della letteratura economica sugli impianti cocleari (IC) è stata condotta con l’obiettivo di sintetizzare i risultati 
degli studi scientifici di costo efficacia degli IC monolaterali e bilaterali (sequenziali/simultanei) in pazienti adulti affetti da sordità pre-
linguale e postlinguale da grave a profonda. La ricerca della letteratura è stata effettuata attraverso le banche dati “PubMed MEDLINE” 
e “Centre for Reviews and Dissemination”. Sono stati inclusi gli studi primari di valutazione economica pubblicati in lingua inglese dal 
2000 al maggio 2010 e finalizzati a quantificare i costi degli IC e a confrontare gli IC monolaterali con le protesi acustiche e gli IC bila-
terali (sequenziali/simultanei) con gli IC monolaterali in termini di costo per unità di efficacia. La revisione sistematica della letteratura 
ha consentito di identificare 4 articoli economici. I costi medi diretti sanitari variano da € 30,026 a € 45,770 nei pazienti con sordità post-
linguale e il costo dell’impianto rappresenta la componente di costo principale. I costi addizionali mediani degli IC bilaterali simultanei e 
sequenziali sono rispettivamente € 21,831 e € 25,459. Il costo medio diretto sanitario degli IC monolaterali è pari a € 31,942 nei pazienti 
con sordità prelinguale. L’IC monolaterale nei pazienti con sordità postlinguale rappresenta un intervento costo efficace se confrontato 
con nessun impianto (€ /QALY varia da € 7,930, € 24,983 a € 33,094). L’IC monolaterale non è un intervento costo efficace per pazienti 
tradizionali con più di 40 anni di sordità (€ 64,604/QALY) e per pazienti con beneficio marginale dall’uso di protesi acustiche con più di 
30 anni di sordità (€ 106,267/QALY). La costo efficacia degli IC monolaterali peggiora con l’aumentare dell’età (€ /QALY da € 23,439 
per pazienti con età < 30 anni a € 55,369 per pazienti con età > 70 anni). Gli IC bilaterali in pazienti con sordità postlinguale sono meno 
costo efficaci che gli IC monolaterali (da € 91,943/QALY a € 102,640/QALY). Gli IC monolaterali sono costo efficaci in pazienti con sordità 
prelinguale (€ /QALY: € 8,096). Data l’esiguità degli studi di valutazione economica in letteratura, ulteriori future ricerche si rendono 
necessarie al fine di supportare i risultati di costo efficacia degli IC negli adulti, per valutare la costo efficacia degli IC bilaterali e per 
stimare i costi diretti non sanitari e i costi indiretti degli IC.
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Introduction and aims
A systematic review of the literature was carried out to 
summarize the results of studies published from January 
2000 to may 2010 on the economic evaluation of cochlear 
implants (Ci) in adult patients affected by severe to pro-
found hearing impairment.
The Ci considered are both monolateral and bilateral (se-
quential/simultaneous) and were analysed in: i) monolater-
al Ci in adult patients; ii) monolateral Ci in elderly patients; 
iii) monolateral Ci in prelingual deaf adult patients; iv) bi-
lateral (sequential or simultaneous) Ci in adult patients.
Methods
This systematic review of the literature was conducted 
with the rationale of an explicit and reproducible meth-
odology according to the criteria of The Cochrane Col-
laboration and others 1 2.
Research strategy
The systematic review of the economic literature was per-
formed  by  a  reviewer  on  September  2009  and  updated 
on  31  may  2010,  interrogating  the  databases  “Pubmed 
mEDlinE” and the Centre for reviews and Dissemination 
(CrD). Pubmed mEDlinE was interrogated using the key-
word “Cochlear implants” AnD (Costs or “Cost Analysis” 
or economics) and limiting the search to the adult popula-
tion (age > 18 years), to publications in English from 2000 to 
may 2010. The database Centre for reviews and Dissemi-
nation, which includes the Economic Evaluation Database 
(nhS EED) and hTA Database, was interrogated by the 
“meSh descriptor Cochlear implants explode all trees with 
qualifier: EC”; it was not possible to insert limits of time, 
population and language. The results obtained from database 
query were imported by refworks version 6.0, a software 
for the management of bibliographic data which allows to 
remove  any  duplicate  records. After  identifying  publica-
tions, two reviewers, working independently, reviewed the 
titles and the abstracts, applying the inclusion and exclusion 
criteria described below. Any differing opinions were re-
solved by discussion between the same reviewers.
Criteria of study selection
inclusion criteria related to primary studies on Ci with the 
following characteristics.
Types of study
•  Partial economic evaluation studies estimating direct 
and indirect costs of Ci;
•  complete economic evaluation studies, including cost-
effectiveness, cost-utility and cost-benefit analyses per-
formed through observational and experimental stud-
ies. Studies published in English from 2000 up to the 
moment of the research (may 2010) were included.
Population
Adults  affected  by  severe  to  profound  hearing  impair-
ment.
Types of comparison
•  Monolateral implants vs. acoustic prosthesis in prelin-
gual deaf adult patients;
•  monolateral implant vs. acoustic prosthesis in elderly 
postlingual deaf patients;
•  simultaneous bilateral implant vs. monolateral implant 
in adult patients;
•  sequential bilateral implant vs. monolateral implant in 
adult patients.
Outcomes
Direct and indirect costs and benefits have been consid-
ered. in particular:
•  cost  for  unit  of  effectiveness  measured  in  physical 
units through an incremental cost effectiveness ratio 
(iCEr);
•  cost for quality adjusted life years (QALY);
•  cost for benefits measured in monetary units;
•  direct and indirect costs of cochlear implantation.
Exclusion criteria
The studies that were not compliant to the inclusion cri-
teria were excluded (in particular unpublished articles, 
unreviewed conference papers, case reports, letters and 
commentaries).
The selected studies were considered eligible, as well as 
those selected through the consultation of bibliographies 
of pertinent publications. Studies were carefully exam-
ined,  assessing  their  methodology,  using  the  available 
tools 3, to evaluate both internal and external validity.
Results
A total of 42 articles were obtained from the database 
search. of these, 30 were extracted from Pubmed and 12 
from the Centre for reviews and Dissemination. Three 
duplicates were eliminated, while pre-defined inclusion 
and exclusion criteria applied to the remaining 39 titles 
and abstracts led to exclusion of 32 studies. The remain-
ing 7 articles were considered eligible, and 1 study identi-
fied by bibliography research was added. The 8 articles 
were analyzed carefully; of these, 4 articles not compliant 
to the quality criteria defined by Evers et al. 3 were ex-
cluded from the review 4-7. A total of 4 articles responding 
positively to the criteria of Evers et al. 3 were included 
(Francis et al. 8, Summerfield et al. 9, uK Cochlear implant 
Study group, uKCiSg 10, molinier et al.) 11. 
The countries examined were the united States 8, great 
Britain 9 10 and France 11. The design was that of a cohort 
retrospective study 8 9 and of a prospective study 10 11. one 
study was single centre 8 and three studies were multicen-Economic evaluation of cochlear implants in adult patients
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tre 9-11. The two English studies 9 10 and the French study 11 
considered adult patients with a mean age of around 50 
years, while Francis et al. 8 considered older patients aged 
between 50 and 80 years and a mean age at recruitment of 
around 66 years. in three articles 8-10, patients were affect-
ed by postlingual deafness. The study by Francis et al. 8 
also includes a group of 6 subjects affected by prelingual 
deafness, while molinier et al. 11 do not specify the type 
of deafness, but postlingual hearing impairment can be 
hypothesized.
in the English studies 9 10, the implant received by the pa-
tients was monolateral; the study by Summerfield et al. 9, 
also evaluates the benefits from the use of bilateral coch-
lear implants. Two studies 8 11 do not state clearly whether 
the implants used are monolateral or bilateral, but it would 
seem that they are monolateral implants when unspeci-
fied.  Furthermore,  Summerfield  et  al 9  and  uKCiSg  10 
divide the group of patients affected by postlingual deaf-
ness and using monolateral Ci into traditional patients and 
patients with marginal benefits on the basis of the results 
of 2 speech intelligibility tests (Bamford-Kowal-Bench, 
BKB and City university of new york, Cuny) using 
acoustic device before surgery. over the last 30 years, 
there has been an extension of the eligibility criteria for 
cochlear implantation, ranging from patients affected by 
profound and total deafness with no benefit from the use 
of acoustic devices to inclusion of patients with marginal 
benefit deriving from the use of acoustic devices. Both 
studies consider no intervention as an alternative to Ci for 
traditional patients and the use of an acoustic device for 
patients with marginal benefit. in three cases, the observa-
tion period is prior to the year 2000 8-10 and in one case 
after the year 2000 11.
Economic assessment consisted in cost analysis 11 and 
cost-utility analysis 8-10. in the cost-utility studies, the 
following were compared: monolateral implant vs. no 
Ci 8-10, monolateral implant vs. acoustic device 9 10, si-
multaneous bilateral vs. monolateral implant, sequential 
bilateral implant vs. no additional implant, simultane-
ous bilateral implant vs. no intervention and simultane-
ous bilateral implant vs. acoustic device 9. in all three 
articles, cost-utility estimates were obtained from meas-
urements repeated on the same subjects before and after 
the Ci.
Three studies adopted the healthcare prospective 9-11; one 
study does not declare the prospective of analysis 8.
in this article, all costs are expressed in 2011 Euro. The 
cost data resulting from the articles were first inflated to 
2011 and then converted in Euros in the case of differ-
ent currencies. in order to inflate to 2011, the consumer 
price index, the hospital and community health services 
(hChS) pay and price index 12, and the gross domestic 
product deflator index for the euro zone were used for 
the following currencies: uSA dollars, English pounds 
and Euros, respectively. Conversion from uSA dollars to 
euro ($ 1 = € 0.70) and from English pounds to Euros 
(£ 1 = € 1.13) was performed on 14 June 2011.
Analysis of cochlear implant costs
Table i summarizes the results of cost analysis performed 
on the studies included in the review. The costs of cochlear 
implantation are estimated in all the four articles consider-
ing the preoperative, operative and postoperative phases. 
The costs evaluated are those related to healthcare, and 
the article by molinier et al. 11 also takes into considera-
tion the non-medical components. indirect costs were not 
considered. one study 9 presents the median costs, while 
the other three studies 8 10 11 deal with the mean costs. Fran-
cis et al. 8 do not specify the method of evaluation of the 
costs; the English studies 9 10 use the top-down approach, 
while the French study 11 adopts a bottom-up approach us-
ing the micro-costing method.
Francis et al. 8 evaluated the direct healthcare costs of 
cochlear implantation taking into account the following 
components: preoperative assessment, Ci costs, surgeon’s 
and anaesthetist’s fees, hospitalization charges and post-
operative expenses including insurance, planning, Ci war-
ranty and hardware costs. The costs were € 30,026 for all 
patients. Total discounted costs for the group of prelingual 
patients was € 31,942.
The mean costs estimated by Summerfield et al. 9 for mon-
olateral cochlear implantation were € 4,276 for preopera-
tive assessment, 79% of which is represented by person-
nel expenses, and € 26,221 for surgical implantation, 79% 
of which related to the costs for the implanted system. 
Personnel costs represented the largest part (81%) of the 
average costs for rehabilitation in the first year after sur-
gery and were € 5,115; maintenance costs in the following 
years were € 1,055.
For surgical implantation, additional median costs evalu-
ated for simultaneous bilateral cochlear implantation were 
€ 21,831 (95% of which was for the implanted system 
and the remaining 5% by personnel costs). median addi-
tional costs evaluated for sequential bilateral cochlear im-
plantation were € 25,459 for surgical implantation, 81% 
of which was represented by the costs for the implanted 
system, 7% by personnel expenses and 6% by the surgi-
cal session. in case of lack of implantation, management 
costs of the hearing aid were estimated by clinicians to 
be equal to a trial visit (€ 149) and a hearing aid (€ 372) 
every three years for about 50% of patients, and to thera-
peutic rehabilitation (€ 447) each year for about 10% of 
patients.
in the same way as for 9, for uKCiSg 10 costs were evalu-
ated on the basis of phase and year of treatment using the 
same cost calculation method. unlike 9, uKCiSg 10 ex-
amined only monolateral Ci and analyzed the cost com-
ponents in greater detail. The phases examined per year 
of treatment refer to preoperative assessment and surgical 
graft (1st year), activation and mapping of the Ci and ther-g. Turchetti et al.
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apeutic rehabilitation (2nd year) and maintenance of the 
patients and their Ci (3rd and successive years). The costs 
of the hearing aid supplied to the patients before cochlear 
implantation were estimated to be € 656 for the trial visit 
and a new hearing aid for each patient in the first year of 
treatment. in the 1st year, the average costs for monola-
teral cochlear implantation were estimated to be € 45,770 
for the phases of evaluation and implantation; 76% of 
these were absorbed by implantation of the system, 13% 
by hospitalization charges and 6% by the surgical ses-
sion. The mapping phase of the implanted system in the 
2nd year of treatment had an average cost of € 8,426, of 
which 95% for hospitalization fees and the remaining 5% 
for replacements and repairs. The phases of maintenance 
for the Ci in the third and fourth years after implantation 
and mapping were estimated to be € 1,698, 75% for hos-
pitalization costs and the remaining 25% for replacement 
and repair expenses, and € 1,629, of which 74% was ab-
sorbed by hospitalization charges and the remaining 26% 
by replacements and repairs. it was estimated that costs 
in the successive years will decrease to € 1,379, 70% of 
which will be assigned to hospitalization charges and the 
remaining 30% to replacements and repairs. The authors 
estimated an additional cost of € 9,851 every 10 years for 
upgrading the Ci processor.
The French prospective and multicentre study 11 evaluated 
direct  healthcare  and  non-healthcare  costs  of  monola-
teral cochlear implantation in the preoperative, operative 
and rehabilitative phases. The total mean cost (± stand-
ard  deviation)  of  cochlear  implantation  was  estimated 
€ 37,030 ± 3,166 per patient, of which 2% was due to the 
costs of preoperative evaluation, 78% to implantation costs 
(hospitalization € 3,517 ± 2,075 for an average period of 
5 ± 3 days, implantation of the device € 25,557 ± 735), 
13% to rehabilitation and 7% (€ 2,605 ± 2,008) to travel 
costs. implantation costs for the device made up the larg-
est part of expenses.
There are three cost-utility studies included in the present 
systematic review 8-10.
Analysis of utility gains with cochlear implants
Three articles 8-10 used the hui to evaluate the quality of 
life of patients using monolateral Cis. hui is a general, 
multi-attribute  and  preference-based  questionnaire  that 
quantitatively measures the general state of health using 
a health utility index score varying from 0.00 (death) to 
1.00 (perfect health). The versions mark ii (hui2) and 
mark iii (hui3), which distinguish deficits in auditory 
and visual functions, were used.
Francis et al. 8 concluded that cochlear implantation was as-
Table I. Cost analysis results of the studies included in the review of cochlear implants in adults.
Author, year of publication, country Cost components, prospective of 
analysis, follow-up
Results (Euro, 2011)
Francis et al., 2002, USA 8 Direct healthcare costs.
Undefined prospective.
Undefined follow-up.
Total costs for cochlear implant:
- € 30,026 for all patients;
- € 30,026 for postlingual deaf patients;
- € 31,942 for prelingual deaf patients.
Summerfield et al., 2002, UK 9 Direct healthcare costs.
Health prospective.
4 years follow-up.
Median cost for different types of cochlear implant:
- preoperative evaluation:
  € 4,276 ICU*, € 0 SBCI**, € 508 ABCI***;
- implantation:
  € 26,221 ICU, € 21,831 SBCI, € 25,459 ABCI;
- rehabilitation in 1st year:
  € 5,115 ICU, € 512 SBCI, € 548 ABCI;
- maintenance in 2nd and 3rd year:
  € 1,055 ICU, € 512 SBCI, € 548 ABCI;
- maintenance in 4th year:
  € 1,055 ICU, € 512 SBCI, € 548 ABCI.
UKCISG, 2004, UK 10 Direct healthcare costs.
Health prospective.
4 years follow-up.
Mean cost (range) of unilateral cochlear implant:
- evaluation and implantation in 1st year:
  € 45,770 (€ 43,161 - € 48,528);
- mapping in 2nd year: € 8,426 (€ 7,489 - € 8,932);
- maintenance in 3rd year: € 1,698 (€ 1,271 – € 2,283);
- maintenance in 4th year: € 1,629 (€ 931 - € 2,283);
- maintenance in nth year: € 1,379 (€ 931-€ 1,818).
Molinier et al., 2009, France 10 Direct costs for health and non-health.
Healthcare prospective.
1 year follow-up.
Mean cost (± standard deviation) total of cochlear implant
 € 37,030 (± 3,166) in 1st year, of which:
- preoperative evaluation: € 756 (± € 589),
- implantation: € 28,991 (± € 2,011),
- rehabilitation: € 4,677 (± € 2,087) and
- travel: € 2,605 (± € 2,008).
* UCI, unilateral CI, ** SBCI: simultaneous bilateral CI; *** ABCI: additional sequential bilateral CIEconomic evaluation of cochlear implants in adult patients
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sociated with a significant increase in quality of life: hui-3 
scores increased from an average preoperative value of 0.37 
to an average postoperative value of 0.61 with significant 
mean difference of 0.24 (p < 0.0001). A significant increase 
in the scores of hui-3 after surgery (0.25, p < 0.0001) was 
observed for 41 postlingual deaf patients, while the appreci-
ated increase for the 6 patients affected by prelingual deaf-
ness did not reach statistical significance (0.21, p ± 0.1). 
Twenty-seven  patients  with  postlingual  deafness  (66%) 
and 3 (50%) patients with prelingual deafness reported that 
their quality of life had significantly improved since they 
started to use Cis.
The study by Summerfield et al. 9 concluded that mon-
olateral implantation, compared to no-intervention (tradi-
tional candidates), allows an average utility gain of 0.188. 
monolateral  implantation,  compared  to  a  hearing  aid, 
allowed reacing an average utility gain in patients (can-
didates with marginal benefit) of 0.077. Similar results 
were obtained in a group of volunteers. The utility gain in 
the group of volunteers was 0.031 both for the simultane-
ous bilateral implant and monolateral implants, and for 
the sequential bilateral implant compared to no additional 
intervention.
uKCiSg 10 claimed that the estimated average utility gain 
with Ci was 0.197 for all patients. Traditional patients 
have an average utility gain which is higher than that of 
patients with marginal benefit (0.214 vs. 0.151); in fact, 
the CI had stronger subjective impact on the former pa-
tients who passed from a lack of word intelligibility to 
the comprehension of some words compared to the latter 
patients whose understanding of a word increased thanks 
to the intervention.
Analysis of cost-utility ratio in cochlear implants
Table ii summarizes the results of cost utility analyses in 
the studies included in the review 8-10. Cost-utility is ex-
pressed in terms of ratio of cost effectiveness and QAly 
gained.
Francis et al. 8 considered an expected average number of 
years of usage of the implant based on 21-year life ex-
pectancy (average age of patients of 63 years). The QAly 
gained are 3.78 for all patients, 3.80 for the postlingual 
group and 3.96 for the prelingual group. Estimated cost-
utility was € 7971 for QAly for all patients, € 7,930 
for QAly for patients affected by postlingual deafness 
and € 8,096 for QAly for prelingual deaf patients. The 
Authors concluded that Ci in adult patients is a highly 
cost-effective intervention for both post-lingual and pre-
lingual deaf patients.
Summerfield et al. 9 evaluated costs and gains of the im-
plant on the basis of an expected average usage of 30 
years. From the evaluation of the authors it may be con-
cluded that:
•  compared to no intervention, monolateral implantation 
allows an incremental gain of 2.45 (2.08-2.83) QAly 
with respect to an incremental cost of € 61,265 which, 
in terms of QAly/cost (plausible range), was € 24,983 
(€ 21,524-29,508);
•  compared  with  hearing  aids,  monolateral  implanta-
tion allows an increase of 1.42 (1.15-1.70) QAly with 
respect to an increased cost of € 58,127 which, ex-
pressed in cost/QAly (plausible range), was € 40,810 
(€ 34,275-50,050);
•  compared to monolateral implantation, simultaneous 
bilateral  implantation  allows  an  incremental  gain  of 
0.44 (0.26-0.62) QAly with respect to an incremental 
utility cost of € 40,213 which, in terms of cost/QAly 
(plausible  range)  was  €  91,943  (€  65,394-154,775); 
sequential bilateral implantation compared to no ad-
ditional implant allowed an incremental gain of 0.44 
(0.26-0.62) QAly with respect to an incremental cost 
of € 44,892 which, expressed in cost/QAly (plausible 
range), was € 102,640 (€ 73,004-172,781);
•  compared to no implant, simultaneous bilateral implant 
allows an incremental gain of 2.89 (2.45-3.33) QAly 
with respect to an incremental cost of € 101,479 which, 
in terms of cost/QAly (plausible range), was € 35,116 
(€  30,466-41,441);  simultaneous  bilateral  implant 
compared to a hearing aid allowed an increment of 1.86 
(1.52-2.21) QAly for an incremental cost of € 97,053 
which, expressed in cost/QAly (plausible range), was 
€ 52,130 (€ 43,979-63,990).
Cost-utility ratios for simultaneous and sequential bilat-
eral implants (compared to monolateral implants and no 
additional implant, respectively) ranged from 3 to 4 times 
more  than  cost-utility  ratios  for  monolateral  implants, 
although the costs for monolateral implants were incre-
mentally higher than those for bilateral implants. There-
fore, the authors concluded that the second implant was 
less cost-effective than the first. in order for the bilateral 
implant to be competitive with the monolateral implant, 
the gain in utility of the second implant was 3 to 4 times 
higher than estimated.
uKCiSg 10 estimated that mean life expectancy of re-
cruited patients is around 30 years. The results of the 
analysis show that the increased average number of QA-
lys gained (95% interval of confidence) thanks to the 
use of the cochlear implant was 2.46 (2.19-2.73) with an 
average incremental cost of € 81,712 (€ 80,774-82,703), 
the cost-utility ratio (€/QAly) was € 33,094 (€ 29,911-
36,972) for all patients. Cost-effectiveness of Ci differed 
according to the type of patients: the cost-utility ratio for 
patients with marginal benefit was significantly higher 
than  that  of  traditional  patients,  €  40,860  (€  32,551-
54,196) and € 30,892 (€ 27,665-34,928), respectively, 
and therefore cost-effectiveness of the Ci was less com-
petitive for patients with marginal benefit than for tradi-
tional patients. The patients with marginal benefit could 
use the Ci for a greater number of years, incurring higher 
total costs for a longer period than traditional patients; g. Turchetti et al.
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indeed, the patients in the former group were younger 
than those of the traditional group (mean age at implan-
tation of 46 years vs. 53 years) and had a longer life ex-
pectancy, and therefore greater use of the Ci (mean age 
expectancy of 34 vs. 28 years, respectively). however, 
the results of the analysis showed a minor gain in terms 
of average incremental number of QAly for the group 
with marginal benefit compared to the traditional group 
(1.99 QAly vs. 2.64 QAly) and few differences in av-
erage incremental costs (€ 81,513 vs. € 81,784). The uni-
lateral Ci was a cost-effective intervention for the cohort 
of patients under study, and was less competitive but in 
any case acceptable for patients with marginal benefit 
compared to traditional patients.
By analyzing cost/QAly in relation to age at implanta-
tion, the authors demonstrated that cost-effectiveness de-
creases with the age of the subjects at implantation but 
within an acceptable range; indeed, the average cost to 
gain a QALY increased from € 23,439 for subjects young-
er than 30 years to € 55,369 for subjects older than 70 
years, as the latter have fewer remaining years on which 
to  accumulate  QAlys.  instead,  considering  the  dura-
tion of profound deafness in the implanted year, the util-
ity gain deriving from the use of cochlear implantation 
diminished with the increase of the duration of deafness 
and under the best preoperative condition, passing from 
a gain of 0.24 utilities for traditional patients with deaf-
ness duration inferior to 10 years to 0.10 QAly for those 
with  deafness  duration  longer  than  40  years  and  from 
a utility gain of 0.18 for patients with marginal benefit, 
with deafness duration inferior to 10 years at 0.06 utility 
for those with deafness duration higher than 30 years. Ci 
were not cost-effective for traditional patients with more 
than 40 years of profound deafness (€ 64,604/QAly) or 
for patients with more than 30 years of profound deaf-
ness, with marginal benefit from the use of the hearing 
aid (€ 106,267/QAly). Therefore, the authors concluded 
that CI is a cost-effective intervention for the majority of 
subjects, including patients older than 70 years at age of 
implant, while the extension of the criteria of eligibility 
to intervention for patients with marginal benefit reduces 
cost-effectiveness.
Discussion
The cost-utility of cochlear implants in adult patients has 
been examined in only a few studies on economic evalu-
Table II. Results of the cost-utility analysis of the studies included in the review on cochlear implants in adults.
Author, year of publication, 
country
Type of comparison Cost components, outcomes, 
discount rate
Results (Euro, 2011)
Francis et al., 2002, USA 8 Cochlear implant vs. no cochlear 
implant.
Direct healthcare costs.
Estimated utilities with HUI-III*.
Yearly discount rate of 3%.
Cost/QALY**:
€ 7,971 for all patients;
€ 7,930 for patients with postlingual 
deafness;
€ 8,096 for patients with prelingual 
deafness.
Summerfield et al., 2002, UK 9 i) Monolateral implant vs. no 
intervention;
ii) Monolateral implant vs. hearing 
aid;
iii) Simultaneous bilateral implant 
vs. monolateral implant;
iv) Additional implant vs. no 
additional implant;
v) Simultaneous bilateral implant vs. 
no intervention;
vi) Simultaneous bilateral implant 
vs. hearing aid.
Direct healthcare costs.
Estimated utilities by the time trade-
off method to evaluate changes 
from the monolateral and bilateral 
implants.
Yearly discount rate of 6%.
Cost/QALY** (plausible range):
i) Monolateral implant vs. no intervention
€ 24,983 (€ 21,524 - € 29,508);
ii) Monolateral implant vs. hearing aid
€ 40,810 (€ 34,275 - € 50,050);
iii) Simultaneous bilateral implant vs. 
monolateral implant € 91,943
(€ 65,394 - € 154,775);
iv) Sequential bilateral implant vs. no 
additional implant
€ 102,640 (€ 73,004 - € 172,781);
v) Simultaneous bilateral implant vs. no 
intervention
€ 35,116 (€ 30,466 - € 41,441);
vi) Simultaneous bilateral implant vs. 
hearing aid
€ 52,130 (€ 43,979 - € 63,990).
UKCISG, 2004, UK 10 Monolateral cochlear implant vs. no 
cochlear implant.
Direct healthcare costs of CI.
Estimated utilities with HUI-III*.
Yearly discount rate of 6%.
Cost/QALY** (95% confidence interval):
€ 33,094 (€ 29,911 - € 36,972) for all 
patients;
€ 30,892 (€ 27,665 - € 34,928) for 
traditional patients;
€ 40,860 (€ 32,551 - € 54,196) for 
patients with marginal benefit.
* HUI-III: Health Utility Index Mark III; ** QALY: Quality Adjusted Life Years.Economic evaluation of cochlear implants in adult patients
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ation. A meta-analysis of the literature prior to the year 
2000 demonstrated that cochlear implantation provides a 
total average improvement of 0.26 utilities in adult pa-
tients affected by profound deafness with cochlear im-
plantation costs of € 12,127 for QAly 12. Therefore, to 
provide an updated synthesis of the results of studies pub-
lished since 2000, a systematic review of literature was 
conducted through a rigorous screening process, which 
made it possible to identify 4 studies on economic evalua-
tion responding to the selection criteria established in the 
present review protocol.
The limited number of studies included in the review and 
the differences between countries, samples, study design, 
follow-up, utility measures, cost components make it dif-
ficult to compare the results obtained or to perform a quan-
titative synthesis of the results through meta-analysis. The 
results of the studies cannot be pooled due to the different 
features utilized. Furthermore, meta-analysis is possible 
when the same treatment is evaluated in a considerable 
number of studies, but in this case meta-analysis applied 
to few heterogeneous studies would produce results that 
would be unreliable and difficult to reproduce.
with regard to economic evaluations in general and co-
chlear implants in particular, the specific features of the 
different contexts (e.g. in terms of organization of the 
healthcare systems) render healthcare resources and as-
sociated costs highly variable within the same country 
and between countries, so that generalizability and trans-
ferability of cost and cost-effectiveness estimates may be 
limited to areas other than the specific case.
From the results of the articles included in this review, we 
conclude that cochlear implantation is a highly expensive 
intervention. Total direct healthcare costs for monolateral 
cochlear implantation in patients affected by postlingual 
deafness  varies,  on  average,  from  about  €  30,026 8  to 
€ 45,770 10, including preoperative evaluation and inter-
vention, in which the expenses for the hearing aid repre-
sent the main component.
mapping costs for monolateral Cis in the second year af-
ter the intervention and of maintenance in the successive 
years decrease over time (from € 8,426 in the second year 
to € 1,379 in the years successive to the fourth year 10). 
Additional average costs for simultaneous and sequential 
bilateral implants were € 21,831 and € 25,459 respective-
ly 9, including preoperative evaluation and intervention. 
The total costs for monolateral Ci was € 31,942 according 
to the estimates of Francis et al. 8.
in patients affected by postlingual deafness, the mean util-
ity gain from the preoperative condition with monolateral 
Ci varies from 0.20 10 to 0.25 8. The mean utility gain was 
higher in traditional patients who did not benefit from 
acoustic devices to patients who benefited only margin-
ally from the use of acoustic devices (0.21 vs. 0.15 10, 0.17 
vs. 0.08 9). mean gain in terms of simultaneous or sequen-
tial bilateral implantation was inferior to the gain with 
monolateral implantation (0.03 9). Patients with prelingual 
deafness had a mean utility gain of 0.21 8.
monolateral Cis in patients affected by postlingual deaf-
ness  represent  a  cost-effective  intervention  when  com-
pared to no-implant for the studies included in the review 
(€ /QAly: € 7,930 according to Francis et al. 8; € 24,983 
according to Summerfield et al. 9; € 33,094 according to 
uKCiSg 10). Cost-effectiveness of monolateral Ci were 
less competitive but in any case acceptable in patients 
with marginal benefit from the acoustic device compared 
to traditional patients without benefit (€ /QAly: € 40,860 
vs. € 30,892 10). According to uKCiSg 10, monolateral 
Cis were not cost effective for traditional patients with a 
duration of deafness over 40 years affected by profound 
hearing  impairment  (€  64,604/QAly)  and  for  patients 
with more than 30 years of profound deafness receiv-
ing marginal benefit from the use of an acoustic device 
(€ 106,267/QAly). with regard to the age at implanta-
tion,  uKCiSg  10  concluded  that  cost-effectiveness  of 
monolateral cochlear implants decreased with increasing 
age, remaining however within an acceptable range (€ /
QALY from € 23,439 for younger subjects 30 years of 
age to € 55,369 for those older than 70 years). Bilateral 
implants in patients affected by postlingual deafness are 
less cost-effective than monolateral implants (simultane-
ous bilateral implant vs. monolateral implant € 91,943/
QAly; bilateral sequential implant vs. no additional im-
plant € 102,640/QAly) 9. monolateral Cis are also cost-
effective in patients affected by prelingual deafness (€/
QAly: € 8,096 according to Francis et al. 8). The estimates 
provided by the studies analyzed – although variable and 
context-dependent – should however be considered as ref-
erences in the literature after the year 2000.
with regard to the design of the study, the retrospective 
cohort  studies 8  9  could  be  affected  by  the  recall  bias, 
namely the reduced capacity of patients to remember past 
events that may have influenced outcomes relative to the 
estimates of preoperative utility. The studies analyzed 8-10 
measured  the  utilities  through  repeated  measurements 
(before and after Ci), and therefore did not compare cases 
(patients with Ci) with controls (patients without Ci); they 
did not indicate what would happen to patients without 
Ci, thus limiting the analysis. however, as profound bi-
lateral deafness allows neither spontaneous recovery nor 
regression, it displays none of the typical features which 
normally limit the design with repeated measurements.
Concerning the cost components analyzed, the study by 
Francis et al. 8 does not report explicitly the prospective of 
analysis adopted in the study and it is therefore difficult to 
establish whether all the significant cost categories have 
been considered. The prospective of society can however 
be excluded, since the indirect costs are not taken into ac-
count. The study does not specify the method employed 
to calculate costs and does not describe in detail the con-
sumed resources and associated cost units. Furthermore, g. Turchetti et al.
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sensitivity analyses were not performed, and for this rea-
son the results can hardly be extended to other contexts.
These limits, as well as the exiguity of the sample and 
the retrospective and single centre study design are partly 
responsible for the lower estimates of cost and cost utility 
presented by the authors with respect to the studies con-
sidered. These estimates can only be referred to the centre 
and to the categories of patients analyzed.
Compared to the other studies 8-10, the estimate of costs 
performed by molinier et al. 11 over a single year covers 
a shorter follow-up period which affects expenses: the 
longer the period of observation, the higher the costs, in 
particular when the expenses for post-operative rehabili-
tation were considered.
not only does the brief follow-up affect the rehabilitation 
costs, but it also influences a number of important cost 
components that are not taken into account. These include 
adverse events and repair or replacement of Ci. unlike 
other investigations 8-10, the French study 11 is the only 
one that considered direct non-medical travel expenses, 
but not the costs for informal care, i.e. the time dedicated 
by relatives and friends to assist the deaf patient. Another 
important cost component neglected by all the four stud-
ies is indirect costs, including the losses of productivity 
that were totally or partially supported by the patients and 
relatives, e.g. work days lost by the patient for treatment 
and  healthcare  assistance,  the  work  time  lost  in  terms 
of the patient’s lower work productivity, and work days 
lost by relatives assisting the patients (vantrappen et al. 14 
estimated that the indirect costs represent 8.9% of total 
costs).
The analysis of costs and cost-utility of simultaneous and 
sequential bilateral Cis is limited to the study by Sum-
merfield et al. 9 who only assess the utilities deriving from 
bilateral implantation not in hearing impaired patients, 
but in normal hearing volunteers (using the time trade off 
method) not affected by deafness and eventual comorbid-
ity. Furthermore, they estimated the resources absorbed 
by the implants as the minimal resources considered plau-
sible by clinicians. recent contrasting outcomes on cost-
utility of bilateral implants were published by Bichey and 
miyamoto 15. This study was not included herein, as the 
authors analyzed a sample of postlingual deaf patients 
aged  6  to  79  years  with  very  different  characteristics, 
without stratifying the results on the basis of paediatric or 
adult patients. unlike Summerfield et al. 9, the outcomes 
of the study showed an overall improvement of 0.48 utili-
ties after bilateral implant with favourable cost/QAly of 
€ 17,132. in order to clarify the relation between age at 
implantation and duration of deafness and quality of life 
of patients using cochlear implants, it would be necessary 
to assess larger samples with respect to those of Francis 
et al. 8 who analyzed 47 elderly patients. moreover, in the 
future it will be necessary to perform studies on braoder 
samples of patients to estimate the cost-utility of cochlear 
implantation in patients affected by prelingual deafness, 
as only one study 8 deals with a group of 6 patients.
Conclusions
The examination of four articles on economic evaluation 
published after 2000 and included in our systematic litera-
ture review allowed identification of the high costs sup-
ported by the healthcare sector for cochlear implantation 
in adult patients affected by post-lingual deafness. of the 
four articles concerning economic assessment, three stud-
ies performed complete cost-quality analyses indicating 
that monolateral cochlear implantation is generally a cost-
effective intervention. when compared to non-interven-
tion, monolateral cochlear implantation has QAly/costs 
varying from about € 25,000/QAly 9 to € 33,000/QAly 10 
for patients affected by postlingual deafness. Cost/QAly 
estimates indicate that monolateral cochlear implantation 
is also a cost-effective intervention for elderly patients, 
while the extension of eligibility criteria to patients mar-
ginally benefiting from the use of hearing aids showed 
a reduction in cost-effectiveness. Cochlear implantation 
is not cost-effective for patients who obtained a benefit 
from the use of hearing aids with a duration of profound 
deafness in the ear receiving the implant that was over 30 
years 10.
Therefore, the duration of deafness should be taken into 
account to establish the eligibility criteria for cochlear im-
plantation. Bilateral implants are less cost-effective than 
monolateral implants as shown by the study by Summer-
field et al. 9
This systematic review of the literature included only one 
study 8 on adult patients affected by prelingual deafness 
showing that monolateral cochlear implantation was also 
cost-effective for this group. The insufficient number of 
patients examined by the study and the lack of referenc-
es in the literature make it necessary to perform future 
research on a wider sample of patients to study the util-
ity costs of cochlear implantation in adult patients with 
prelingual deafness. Since the studies analyzed consider 
only direct healthcare costs, except for one article which 
also assessed the non-medical direct costs for travelling, 
future economic assessment studies should consider the 
other categories of non-medical direct costs and indirect 
costs. There is a limited number of articles published, so 
that the results cannot easily be generalized to contexts 
different from those specific to individual studies. Future 
searches through economic assessment studies will thus 
be necessary to:
a. support the cost-effectiveness results of Cis in adults;
b. evaluate  cost-effectiveness  of  simultaneous  and  se-
quential bilateral implants;
c. evaluate the components of direct and indirect non-
medical costs as well as direct medical costs in cost-
effectiveness analysis.Economic evaluation of cochlear implants in adult patients
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